Annual report [Section 13 and 15(d), not S-K Item 405]

SEGMENT INFORMATION

v3.25.0.1
SEGMENT INFORMATION
12 Months Ended
Dec. 31, 2024
SEGMENT INFORMATION  
SEGMENT INFORMATION

15. SEGMENT INFORMATION

The following table presents segment information for the periods presented:

​

​

​

​

​

​

​

​

​

​

​

​

​

Year Ended December 31,

​

 

2024

    

2023

    

2022

​

​

(in thousands)

Total Revenues

​

$

179,278

​

$

116,882

​

$

120,242

Less:

​

​

​

​

​

​

​

​

​

Employee related expenses

​

​

69,807

​

​

63,429

​

​

69,477

Commercial related expenses

​

​

26,996

​

​

24,310

​

​

23,846

Cost of product sales

​

​

18,647

​

​

7,110

​

​

1,749

Consultants and third-party services

​

​

15,532

​

​

17,942

​

​

22,218

Outside clinical trial related expenses

​

​

10,978

​

​

9,694

​

​

29,981

Other segment items

​

​

13,126

​

​

14,888

​

​

28,521

Interest expense, net

​

​

5,826

​

​

4,600

​

​

3,023

Provision for income taxes

​

​

881

​

​

—

​

​

—

Segment income (loss)

​

$

17,485

​

$

(25,091)

​

$

(58,573)

​

There is no reconciling items or adjustments between segment income (loss) presented above and net income (loss) as presented in our statements of operations. The CODM does not review assets in evaluating the segment results and therefore such information is not presented.

For details of revenues disaggregated by category, see “Note 3 – Revenues”.

Employee related expenses primarily comprised salaries, employee benefits, other employee related expenses and stock-based compensation expense. For details of stock-based compensation expense, see “Note 6 – Stock-Based Compensation.”

Other segment items for the periods presented primarily comprised travel related expenses, business insurance, taxes and licenses, and facility related expenses. Other segment items for the year ended December 31, 2022 also include restructuring costs and IPR&D.